New Drug Causes 20 Percent Weigh Loss in Early Amgen Results
Amgen also tested MariTide in a population with Type 2 diabetes, a group that tends to lose less weight with the new obesity ...
Stock Market Today: Stocks mixed as markets navigate Trump tariff risks
Stocks are shrugging off a new Trump tariff threat as the President-elect vows sweeping levies on the biggest U.S. trading ...
Medicare Could Pay for Wegovy. Don’t Count On It.
The Biden administration said it would allow the program to pay for GLP-1 anti-obesity drugs, but the Trump administration ...
BioSpace48m
‘Bulls Disappointed’ as Amgen’s MariTide Demonstrates 20% Weight Loss
Amgen’s MariTide results are at the lower end of investors’ expectation of 20% to 25% weight loss. The much-anticipated ...
Amgen drags Dow lower after weight-loss drug data disappoints Wall Street
Shares of biotech company Amgen slid Tuesday morning, trading around 12% lower. The drop was significant enough to drag the entire Dow Jones Industrial Average lower, because the index is ...
Amgen down 4% after reporting MariTide weight loss study results
Shares of Amgen (AMGN) are down $11.49, or 4%, to $282.51 in pre-market trading after the company reported data at 52 weeks in a Phase 2 study ...
STAT42m
Pharmalittle: We’re reading about Medicare obesity drug coverage, a first-of-its-kind 340B analysis, and more
The Biden administration is proposing a major expansion of how Medicare and Medicaid cover Wegovy and Zepbound ...
Amgen, Boeing share losses lead Dow's 200-point fall
The Dow Jones Industrial Average is falling Tuesday morning with shares of Amgen and Boeing facing the biggest drops for the index. Shares of Amgen and Boeing have contributed to the index's intraday ...
McKnight's Senior Living30m
1999 to 2020 saw twofold increase in alcohol-related mortality in the US
Increases of 2.5-fold were seen for women, 2.4-fold for Asians and Pacific Islanders, and 2.5-fold in the Midwest.